AUTL Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

24.32M

+83747.79%

-0.399

+343.28%

30.28M

+237.11%

-0.210

-20.33%

-0.183

+1.85%

Estimates Revision

The market is revising Upward the revenue expectations for Autolus Therapeutics plc (AUTL) for FY2025, with the revenue forecasts being adjusted by 0.28% over the past three months. During the same period, the stock price has changed by 2.84%.

Revenue Estimates for FY2025

Revise Upward

+0.28%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+2.84%

In Past 3 Month

5 Analyst Rating

Wall Street analysts forecast AUTL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AUTL is 7.68 USD with a low forecast of 5.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

5.00

Averages

7.68

High

10.00

Current: 0.000

Low

5.00

Averages

7.68

High

10.00

Needham

Buy

maintain

$10 -> $11

2025-12-29

Reason

Needham

Price Target

$10 -> $11

2025-12-29

maintain

Buy

Reason

Needham raised the firm's price target on Autolus Therapeutics to $11 from $10 and keeps a Buy rating on the shares. The firm also names Autolus a top pick for 2026. While Aucatzyl's launch has been impressive with $76M in sales, investors remain skeptical of Autolus, questioning if the company can reach breakeven, the analyst tells investors in a research note. Needham disagrees with skepticism, saying the shares offers an "attractive valuation" and a "strong opportunity for value creation in 2026." Data from the the FELIX study and obe-cel results in relapsed/refractory acute lymphoblastic leukemia indicate an expanding addressable market, contends the firm. Its modeling has Autolus reaching breakeven by 2028 based on Aucatzyl sales alone. Needham believes obe-cel in lupus nephritis receives little recognition at current share levels, which could change with clinical updates in the first half of 2026.

Needham

Gil Blum

Strong Buy

Reiterates

$10

2025-04-10

Reason

Needham

Gil Blum

Price Target

$10

2025-04-10

Reiterates

Strong Buy

Reason

Truist Securities

Asthika Goonewardene

Strong Buy

Maintains

$11 → $10

2025-04-01

Reason

Truist Securities

Asthika Goonewardene

Price Target

$11 → $10

2025-04-01

Maintains

Strong Buy

Reason

Truist lowered the firm's price target on Autolus Therapeutics to $10 from $11 and keeps a Buy rating on the shares. The firm is updating its model and estimates for Autolus, slightly lowering our price target as it removes AUTO4 from its valuation, the analyst tells investors in a research note. Truist adds it is assigning no value to autoimmune indications, but this could change following Autolus' April R&D day.

Wells Fargo

Yanan Zhu

Buy

Maintains

$8 → $6

2025-03-21

Reason

Wells Fargo

Yanan Zhu

Price Target

$8 → $6

2025-03-21

Maintains

Buy

Reason

Needham

Gil Blum

Strong Buy

Reiterates

$10

2025-01-13

Reason

Needham

Gil Blum

Price Target

$10

2025-01-13

Reiterates

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Autolus Therapeutics PLC (AUTL.O) is -1.93, compared to its 5-year average forward P/E of -3.04. For a more detailed relative valuation and DCF analysis to assess Autolus Therapeutics PLC 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.04

Current PE

-1.93

Overvalued PE

-1.32

Undervalued PE

-4.76

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.03

Current EV/EBITDA

-1.89

Overvalued EV/EBITDA

-0.34

Undervalued EV/EBITDA

-3.73

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

128.80

Current PS

3.76

Overvalued PS

295.46

Undervalued PS

-37.86

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

AUTL News & Events

Events Timeline

No data

News

7.5

01-06Newsfilter

Autolus Evaluates Cellares' Automated Platform for Manufacturing Expansion

9.0

2025-12-29Benzinga

Ultragenyx Shares Plunge 42% Following Phase 3 Study Failures for Setrusumab

8.5

2025-12-29Benzinga

DigitalBridge Group Inc Acquired by SoftBank Group for Approximately $4 Billion

People Also Watch

Frequently Asked Questions

What is Autolus Therapeutics PLC (AUTL) stock price today?

The current price of AUTL is 1.81 USD — it has decreased -5.24 % in the last trading day.

What is Autolus Therapeutics PLC (AUTL)'s business?

Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.

What is the price predicton of AUTL Stock?

What is Autolus Therapeutics PLC (AUTL)'s revenue for the last quarter?

Autolus Therapeutics PLC revenue for the last quarter amounts to 21.19M USD, decreased % YoY.

What is Autolus Therapeutics PLC (AUTL)'s earnings per share (EPS) for the last quarter?

Autolus Therapeutics PLC. EPS for the last quarter amounts to -0.30 USD, decreased -3.23 % YoY.

What changes have occurred in the market's expectations for Autolus Therapeutics PLC (AUTL)'s fundamentals?

How many employees does Autolus Therapeutics PLC (AUTL). have?

Autolus Therapeutics PLC (AUTL) has 647 emplpoyees as of January 10 2026.

What is Autolus Therapeutics PLC (AUTL) market cap?

Today AUTL has the market capitalization of 481.72M USD.